Niall O'Donnell, Director at Reneo Pharmaceuticals, Inc. (RPHM), bought 125,000 shares at $8.00 ($1.0M) on 2023-05-08, disclosed to the SEC on 2023-05-10.
Open-market purchase of $1.0M RPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| RPHM | BUY | 2021-04-15 | $3.0M | — | Filing → |
| SPRB | BUY | 2020-10-16 | $3.8M | — | Filing → |
| MIRM | BUY | 2019-07-24 | $4.5M | — | Filing → |